In this article, we will take a look into Eli Lilly and Co's (NYSE:LLY) DCF analysis, a reliable and data-driven approach to ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

Senator Ron Wyden (D-Oregon) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had bought between $50,001 and $100,000 ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...

Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...